博纳吐单抗治疗急性B淋巴细胞白血病的疗效和安全性

Efficacy and safety of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

博纳吐单抗作为靶向CD19和CD3的新型双特异性抗体,可诱导T淋巴细胞精准靶向CD19阳性B淋巴细胞使其凋亡,是目前国内唯一被批准用于治疗血液恶性肿瘤的双特异性抗体,对初诊断、复发/难治性、微小残留病阳性的急性B淋巴细胞白血病(B-ALL)患者有较好的疗效,可改善患者生存期,且耐受性良好。对其深入研究可为博纳吐单抗用于B-ALL患者的诱导治疗、挽救治疗和序贯造血干细胞移植提供理论依据和新的思路。

Blinatumomab,as a novel bispecific antibody targeting CD19 and CD3,can induce T lymphocytes to precisely target CD19 positive B lymphocytes to apoptosis.At present,it is the only bispecific antibody approved for the treatment of hematological malignancies in China.Blinatumomab is effective in the treatment of newly diagnosed,relapsed/refractory,minimal residual disease positive patients with B-cell acute lymphoblastic leukemia(B-ALL).It can improve the survival of the patients and is well tolerated.The further study of blinatumomab can provide theoretical basis and new ideas for induction therapy,salvage therapy and subsequent hematopoietic stem cell transplantation in patients with B-ALL.